Forest rides Namenda growth wave past analysts' earnings estimates

Forest Laboratories ($FRX) handily beat analyst expectations with Q3 earnings of 36 cents per share, on unexpectedly strong sales of its Alzheimer's disease drug Namenda and brand-new antidepressant Viibryd. New CEO Brent Saunders said he's looking at rejigging the company's strategy to prepare for Namenda's patent expiration in 2015. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…